GLP-1 drugs like Ozempic and Wegovy could become the new “all medication”

GLP -1 agonists – including semaglutides such as Ozempic and Wegovy and Tirzepatides such as Mounjaro and Zepbound – were originally intended to treat type 2 diabetes and obesity.

But in recent months, studies have shown that these popular drugs can have many other health benefits.

Some have even said that GLP-1 could possibly become the new “any medication”.

A Mediterranean diet associated with other lifestyle changes the risk of diabetes

DRE Angela Fitch, Knownwell co-founder and chief doctor, an “inclusive weight” health care company based in Boston, said that it would warn against the labeling of any drug as a “all medication”, but should that GLP-1 are promising.

“GLP-1s are currently approved for the treatment of obesity, type 2 diabetes, secondary prevention of cardiovascular disease, hepatic diseases associated with metabolic, chronic kidney disease in patients with diabetes and sleep apnea,” she told Fox News.

GLP -1 agonists – including semaglutides such as Ozempic and Wegovy and Tirzepatides such as Mounjaro and Zepbound – were originally intended to treat type 2 diabetes and obesity. (istock)

“Additional research is necessary to determine their effectiveness in the treatment of other chronic conditions.”

However, drugs have shown a “notable promise” in areas such as the treatment of drug addiction and the improvement of neurological conditions like Alzheimer, said Fitch.

The DNA test reveals which children are more at risk of obesity in adulthood

“They lower blood pressure, lower cholesterol and decrease visceral adiposity,” she said. “They also considerably improve the quality of life of patients. They have many clinical indications today and many others to come.”

Higher advantages of GLP-1

Fitch listed the following main advantages of GLP-1 drugs.

• Facilitate effective fat loss and maintenance
• Control blood sugar and prevent diabetes in patients at risk
• Reduce blood pressure
• Improvement of lipids (achieving a lipid profile of healthy blood)
• Reduce the risk of heart disease and kidney disease

“These are not amenities. These are the Holy Grail of modern medicine.”

Dr. Brett Osborn, an expert in neurosurgeon and Florida longevity, believes that GLP-1 are “here to stay”.

“These drugs are not only dealing with obesity-they are already promising in everything, from cardiovascular disease to neurodegenerative diseases to dependence,” he told Fox News Digital.

“I have already said it, and I repeat: they are not amenities. They are the Holy Grail of modern medicine.”

Potential risks and disadvantages

The most common side effects of GLP-1 drugs are linked to gastrointestinal.

These include nausea, vomiting, diarrhea, constipation and bloating, especially during the initial dose climbing period, according to Fitch.

In recent months, studies have shown that drugs like Ozempic and Wegovy may have many other health benefits. (istock)

“These symptoms often improve over time, but can limit certain patients,” she said.

The other more serious, although rare risks, in particular pancreatitis, gallbladder disease and potential renal lesions – especially if severe dehydration occurs due to vomiting, warned the expert.

“Not everyone tolerates them, and we have no complete handle on long -term side effects.”

Dr. Marc Siegel, Fox News principal medical analyst, previously warned the side effects of GLP-1.

“Not everyone tolerates them well, and we have no complete handle on long-term side effects,” he told Fox News Digital at the time.

“I certainly think that they are useful – and may think of many situations where they decrease the risks of heart disease, stroke, diabetes and cancer as well as the need for bariatric surgery – but they are surely not a one -sized size and are especially not a first line therapy.”

Are all GLP-1s equal?

Not all the agonists of GLP-1 receptors are the same, warned Fitch.

“Although they all act on the same basic way, their effectiveness, their secondary effect profiles and their cardiovascular advantages can vary considerably,” she told Fox News Digital.

“These drugs not only deal with obesity – they are already promising in everything, from cardiovascular disease to neurodegenerative diseases to dependence.” (istock)

The semaglutide, such as Ozempic and Wegovy, is currently considered the most powerful GLP-1 for weight loss and glycemic control, said Fitch, with proofs of cardiovascular profit in people with type 2 diabetes and obesity.

The semaglutide has also been approved as a puree treatment (steathepatitis associated with metabolic dysfunction, a fatty type of liver disease).

Click here to obtain the Fox News app

“The shooting (Mounjaro, Zepbound) is a double GIP / GLP-1 agonist and has shown even greater weight loss in the tests with a similar side effect profile,” said Fitch.

“The shooting is approved for sleep apnea and undergoes clinical trials for other indications.”

“The shooting (Mounjaro, Zepbound) is a double GIP / GLP-1 agonist and has shown even greater weight loss in tests with a similar side effect profile,” said an expert. (Getty Images)

Based on its own clinical experience, Osborn has reiterated that in many cases, the shooting is a “higher agent”.

“It is a double incretine, which means that it targets two biochemical pathways,” he told Fox News Digital. “Unsurprisingly, therefore, for patients who set on Wegovy, Zepbound often jumps on weight loss.”

What to know before starting a GLP-1

GLP-1s are not a “magic solution”, said Fitch, noting that diet, exercise, sleep and behavioral changes are always essential to harvest all advantages.

“Before taking GLP-1, people should also know that side effects are common and that consistent clinical care and surveillance are necessary to ensure safety and efficiency,” she advised.

Click here to register for our Health Newsletter

“This is not something to which people should simply access via an internet form and treat themselves without good complete longitudinal care.”

For chronic conditions such as obesity or type 2 diabetes, Fitch recommends long -term, even indefinite use, as the best approach.

The diet, exercise, sleep and behavioral changes are essential to collect the total advantages of GLP-1, said an expert. (istock)

“The lowering of the dose can become a viable maintenance strategy once a healthy weight is reached, although this approach is still under study,” she said.

“Patients should consult their doctor to determine the course of action that is best in accordance with their specific needs.”

For more health items, visit www.foxnews.com/health

Anyone who is interested in starting a GLP-1 medication should consult a doctor to discuss potential advantages and risks.